17 patents
Utility
Methods of inhibiting pathological angiogenesis
9 Jan 24
This invention is based on the discovery that many eye conditions associated with aging are mediated at least in part by cells bearing a senescent phenotype.
Pam Tsuruda, Jill Hopkins, Harry Sweigard, Yan Poon, Jamie Dananberg, Daniel Marquess, Nathaniel David
Filed: 25 Aug 21
Utility
Treating cognitive decline and other neurodegenerative conditions by selectively removing senescent cells from neurological tissue
7 Jun 22
Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent.
Remi-Martin Laberge, Judith Campisi, Marco Demaria, Nathaniel David, James L. Kirkland, Tamar Tchkonia, Yi Zhu, Darren J. Baker, Jan M. A. van Deursen
Filed: 26 Sep 19
Utility
Methods of inhibiting pathological angiogenesis
28 Sep 21
This invention is based on the discovery that many eye conditions associated with aging are mediated at least in part by cells bearing a senescent phenotype.
Pam Tsuruda, Jill Hopkins, Harry Sweigard, Yan Poon, Jamie Dananberg, Daniel Marquess, Nathaniel David
Filed: 14 Feb 20
Utility
Acylsulfonamide derivatives for treating senescence-associated diseases and disorders
7 Sep 21
Bradley Backes, Thomas W. von Geldern, Bing Chen
Filed: 16 Dec 16
Utility
Phospholidines that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
17 Aug 20
Anne-Marie Beausoleil, Ryan Hudson
Filed: 28 May 19
Utility
Conjugates that are configured for targeted delivery of therapeutic compounds to senescent cells
17 Aug 20
Disclosed are agents (e.g., peptides, polypeptides, proteins, small molecules, antibodies, and antibody fragments that target senescent cells) and methods of their use for imaging senescent cells in vivo and for treating or preventing cancer, age-related disease, tobacco-related disease, or other diseases and disorders related to or caused by cellular senescence in a mammal.
Shayne Squires
Filed: 26 Mar 18
Utility
Phosphonamidates that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
10 Aug 20
Anne-Marie Beausoleil, Ryan Hudson
Filed: 28 May 19
Utility
Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
20 Jul 20
Anne-Marie Beausoleil, Ryan Hudson
Filed: 18 Jun 19
Utility
Acyl phosphonamidates and acyl benzylamines that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
6 Jul 20
This disclosure provides compounds with Bcl inhibitory activity based on a new chemical scaffold.
Anne-Marie Beausoleil, Ryan Hudson
Filed: 28 May 19
Utility
Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer
22 Jun 20
The proteasome inhibitors of this invention include peptide-based compounds with a short linear sequence of amino acids.
Ryan Hudson, Anne-Marie Beausoleil, F. Anthony Romero, Remi-Martin Laberge
Filed: 23 Apr 19
Utility
Technology to inhibit vascular changes that lead to vision loss in the eye
16 Mar 20
This invention is based on the discovery that many eye conditions associated with aging are mediated at least in part by cells bearing a senescent phenotype.
Pam Tsuruda, Jill Hopkins, Harry Sweigard, Yan Poon, Jamie Dananberg, Daniel Marquess, Nathaniel David
Filed: 14 Oct 18
Utility
Composition comprising a gene vector that selectively depletes P16 positive senescent cells
3 Feb 20
Polypeptides, viruses, methods and compositions provided herein are useful for the selective elimination of senescent cells.
Serge Lichtsteiner, Nathaniel David
Filed: 9 Jun 19
Utility
Removing senescent cells from a mixed cell population or tissue using a phosphoinositide 3-kinase (PI3K) inhibitor
30 Dec 19
Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent.
Remi-Martin Laberge, James L. Kirkland, Tamar Tchkonia, Yi Zhu, Nathaniel David, Alain Philippe Vasserot, Darren J. Baker, Bennett G. Childs, Jan M. A. van Deursen
Filed: 15 May 18
Utility
Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer
30 Dec 19
The proteasome inhibitors of this invention include peptide-based compounds with a short linear sequence of amino acids.
Ryan Hudson, Anne-Marie Beausoleil, F. Anthony Romero, Remi-Martin Laberge
Filed: 11 Aug 19
Utility
Compositions of matter for treatment of ophthalmic conditions by selectively removing senescent cells from the eye
18 Nov 19
Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent.
Remi-Martin Laberge, Judith Campisi, Marco Demaria, Nathaniel David, Alain Philippe Vasserot, James L. Kirkland, Tamar Tchkonia, Yi Zhu, Darren J. Baker, Bennett G. Childs, Jan M. A. van Deursen
Filed: 17 Apr 18
Utility
Unit dose of an aryl sulfonamide that is effective for treating eye disease and averting potential vision loss
18 Nov 19
Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent.
Remi-Martin Laberge, Judith Campisi, Marco Demaria, Nathaniel David, Darren J. Baker, James L. Kirkland, Tamar Tchkonia, Yi Zhu, Jan M. A. van Deursen, Alain Philippe Vasserot, Bennett G. Childs
Filed: 12 Jun 18
Utility
Chemical entities that kill senescent cells for use in treating age-related disease
30 Sep 19
Disclosed herein are compounds that are effective for treatment of various disease states associated with senescence.
Nathaniel David
Filed: 7 Mar 18
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first